Pharmacokinetics, dynamics and toxicity of docetaxel: Why the Japanese dose differs from the Western dose
H Kenmotsu, Y Tanigawara - Cancer science, 2015 - Wiley Online Library
Docetaxel (Taxotere®) has been one of the most important chemotherapeutic drugs for
cancer treatment since 1996. Although a large number of clinical studies have been …
cancer treatment since 1996. Although a large number of clinical studies have been …
The evolution of therapies in non-small cell lung cancer
V Boolell, M Alamgeer, DN Watkins, V Ganju - Cancers, 2015 - mdpi.com
The landscape of advanced non-small lung cancer (NSCLC) therapies has rapidly been
evolving beyond chemotherapy over the last few years. The discovery of oncogenic driver …
evolving beyond chemotherapy over the last few years. The discovery of oncogenic driver …
Non–small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology
This selection from the NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC)
focuses on targeted therapies and immunotherapies for metastatic NSCLC, because …
focuses on targeted therapies and immunotherapies for metastatic NSCLC, because …
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
Background Immune checkpoint inhibitors are a new standard of care for patients with
advanced non-small-cell lung cancer (NSCLC) without EGFR tyrosine kinase or anaplastic …
advanced non-small-cell lung cancer (NSCLC) without EGFR tyrosine kinase or anaplastic …
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
S Novello, F Barlesi, R Califano, T Cufer… - Annals of …, 2016 - annalsofoncology.org
Primary lung cancer remains the most common malignancy after non-melanocytic skin
cancer, and deaths from lung cancer exceed those from any other malignancy worldwide [1] …
cancer, and deaths from lung cancer exceed those from any other malignancy worldwide [1] …
[HTML][HTML] Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced NSCLC: CheckMate 078 randomized phase III …
Introduction Data on immuno-oncology agents in Chinese patients are limited despite a
need for new therapies. We evaluated the efficacy and safety of nivolumab in a …
need for new therapies. We evaluated the efficacy and safety of nivolumab in a …
Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302)
B Han, K Li, Y Zhao, B Li, Y Cheng, J Zhou, Y Lu… - British journal of …, 2018 - nature.com
Background: Anlotinib (AL3818) is a novel multitarget tyrosine kinase inhibitor, inhibiting
tumour angiogenesis and proliferative signalling. The objective of this study was to assess …
tumour angiogenesis and proliferative signalling. The objective of this study was to assess …
The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV
H Akamatsu, K Ninomiya, H Kenmotsu… - International journal of …, 2019 - Springer
According to rapid development of chemotherapy in advanced non-small cell lung cancer
(NSCLC), the Japan Lung Cancer Society has been updated its own guideline annually …
(NSCLC), the Japan Lung Cancer Society has been updated its own guideline annually …
[HTML][HTML] Skin problems and EGFR-tyrosine kinase inhibitor
T Kozuki - Japanese journal of clinical oncology, 2016 - ncbi.nlm.nih.gov
Epidermal growth factor receptor inhibition is a good target for the treatment of lung, colon,
pancreatic and head and neck cancers. Epidermal growth factor receptor-tyrosine kinase …
pancreatic and head and neck cancers. Epidermal growth factor receptor-tyrosine kinase …
Machine learning based personalized drug response prediction for lung cancer patients
Lung cancers with a mutated epidermal growth factor receptor (EGFR) are a major
contributor to cancer fatalities globally. Targeted tyrosine kinase inhibitors (TKIs) have been …
contributor to cancer fatalities globally. Targeted tyrosine kinase inhibitors (TKIs) have been …